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Stem cells are proposed to segregate chromosomes asymmetrically
during self-renewing divisions so that older (‘immortal’) DNA
strands are retained in daughter stem cells whereas newly syn-
thesized strands segregate to differentiating cells1–6. Stem cells
are also proposed to retain DNA labels, such as 5-bromo-2-
deoxyuridine (BrdU), either because they segregate chromosomes
asymmetrically or because they divide slowly5,7–9. However, the
purity of stem cells among BrdU-label-retaining cells has not been
documented in any tissue, and the ‘immortal strand hypothesis’
has not been tested in a system with definitive stem cell markers.
Here we tested these hypotheses in haematopoietic stem cells
(HSCs), which can be highly purified using well characterized
markers. We administered BrdU to newborn mice, mice treated
with cyclophosphamide and granulocyte colony-stimulating
factor, and normal adult mice for 4 to 10 days, followed by 70 days
without BrdU. In each case, less than 6% of HSCs retained BrdU
and less than 0.5% of all BrdU-retaining haematopoietic cells were
HSCs, revealing that BrdU has poor specificity and poor sensitivity
as an HSC marker. Sequential administration of 5-chloro-2-
deoxyuridine and 5-iodo-2-deoxyuridine indicated that all HSCs
segregate their chromosomes randomly. Division of individual
HSCs in culture revealed no asymmetric segregation of the label.
Thus, HSCs cannot be identified on the basis of BrdU-label reten-
tion and do not retain older DNA strands during division, indi-
cating that these are not general properties of stem cells.
The immortal strand hypothesis was proposed as a mechanism by
which stem cells could avoid accumulating mutations that arise dur-
ing DNA replication2. Whereas most cells segregate their chromo-
somes randomly1,10, it was argued that adult stem cells in steady-state
tissues might retain older DNA strands during asymmetric self-
renewing divisions, segregating newly synthesized strands to daugh-
ter cells fated to differentiate (Fig. 1a). Evidence has supported this
model in some epithelial stem cells1, neural stem cells3, mammary
epithelial progenitors4 and muscle satellite cells5,6. A related idea is
that adult stem cells in steady-state tissues might consistently retain
DNA labels. This could be because chromosomes segregate randomly
but stem cells divide more infrequently than other cells (Fig. 1b), or
alternatively because the older DNA strand is labelled and segregated
asymmetrically (Fig. 1c). Tritiated thymidine8 or histone7 label-
retaining cells from the hair follicle are enriched for epithelial stem
cells, although the purity remains uncertain. Label-retaining cells
have also been identified in the haematopoietic system9,11, in mam-
mary epithelium12, in intestinal epithelium1,13 and in the heart14, but
the purity of stem cells among these label-retaining cells has not been
tested. As a result, it remains unclear whether label retention can
consistently identify stem cells with specificity or sensitivity.
Under steady-state conditions in adult bone marrow, all HSCs
divide regularly but infrequently15 to sustain haematopoiesis and to
maintain nearly constant numbers of HSCs. As a result of this obser-
vation, as well as the finding that HSC divisions yield asymmetric
outcomes in culture16, it has been proposed that adult HSCs divide
asymmetrically16, although the rarity of HSCs in vivo and their
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Figure 1 | Contrasting predictions regarding stem cell labelling on the basis
of the immortal strand model versus random chromosome segregation.
a, According to the immortal strand model2, stem cells divide
asymmetrically under steady-state conditions and BrdU is incorporated into
newly synthesized DNA strands that are asymmetrically segregated into
differentiating daughter cells with each round of division, such that stem
cells retain only the unlabelled older DNA strands. b, In contrast, if
chromosomes segregate randomly, then BrdU-labelled chromosomes will be
stochastically lost over multiple rounds of divisions. c, In the immortal
strand model, if stem cells divide symmetrically then BrdU can be
incorporated into DNA strands that become the ‘older’ strands once stem
cells resume asymmetric division. Under these circumstances, the BrdU1
older strands would be retained indefinitely in stem cells. d, In contrast, if
chromosome segregation is random then BrdU1 chromosomes are
stochastically lost over time after BrdU is discontinued.
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relative quiescence has made it impossible to confirm this directly.
Nonetheless, if BrdU-label retention and/or asymmetric chromo-
some segregation are general properties of adult stem cells, then
either or both of these characteristics should be evident in HSCs,
depending on experimental conditions.
To test the rate at which HSCs enter the cell cycle we administered
BrdU to mice for 1, 4 or 10 days, and then sorted HSCs onto microscope
slides and stained with an anti-BrdU antibody. HSCs were sorted as
CD1501CD48–CD41–lineage–Sca-11c-kit1 cells (Fig. 2a). This popu-
lation contains all of the detectable HSC activity in bone marrow, and
47% of single cells from this population give long-term multilineage
reconstitution in irradiated mice17. After 1–10 days of BrdU treatment,
51–94% of whole bone marrow cells and 6.5–45.9% of CD1501CD48–
CD41–lineage–Sca-11c-kit1 HSCs became BrdU1 (Fig. 2c, d). We cal-
culated the rate at which HSCs entered the cell cycle15 to be 6.0% per day
(Fig. 2e). Consistent with this, only 3.2% of CD1501CD48–CD41–
lineage–Sca-11c-kit1 cells were in S/G2/M phase of the cell cycle at
any one time (Supplementary Fig. 3). These results are similar to a
previous study that identified HSCs using different markers15.
The linearity of BrdU incorporation over time (Fig. 2e) suggests
that most HSCs divide at a similar rate. If a minority of HSCs divided
more rapidly, consistently more than 6.0% of HSCs should have
incorporated BrdU after one day; however, we did not observe this
(Fig. 2d). If a minority of HSCs were more deeply quiescent than most
other HSCs, these HSCs should remain BrdU-negative, even after long
periods of BrdU treatment. This also has not been observed, because
more than 99% of HSCs are labelled after 6 months of BrdU treat-
ment15. Therefore, there is no evidence for more rapidly dividing or
more slowly dividing subsets of long-term self-renewing HSCs under
steady-state conditions, although we cannot exclude the possibility
that a minority of HSCs divide more slowly than 6.0% per day.
To evaluate retention of the BrdU label, we administered BrdU for
10 days, followed by 70 days without BrdU (a 70-day ‘chase’), like
previous studies in the haematopoietic system9,11. Given that 6.0% of
HSCs entered the cell cycle each day and 46% of HSCs were labelled
after 10 days of BrdU treatment (Fig. 2d), we modelled the fraction of
HSCs that would be expected to retain BrdU over time (Fig. 3a; see
Methods for explanation).
Under these experimental conditions, if HSCs follow the immortal
strand model they should lose their BrdU label one division after
BrdU is discontinued because the labelled chromosomes would be
segregated to differentiating daughter cells (Fig. 1a); therefore, only
0.6% of HSCs would be expected to retain BrdU after the 70-day
chase (Fig. 3a). If HSCs segregate chromosomes randomly, then
BrdU would be lost stochastically over time and the fraction of
BrdU1 HSCs after a 70-day chase would depend on the threshold
of BrdU required for detection. If the threshold is equivalent to 0.5n
labelled chromosomes (one-quarter of the genome), this level of
BrdU dilution could be achieved in cells that had divided 1 or 2 times
after BrdU was discontinued (depending on whether they had
divided once or twice in the presence of BrdU), and only 1.4% of
HSCs would be expected to retain BrdU after the 70-day chase
(Fig. 3a). In contrast, if the threshold of detection is equivalent to
0.0625n labelled chromosomes, this could be achieved on average in
cells that had divided 4 or 5 times after BrdU was discontinued, and
19.8% of HSCs would be expected to retain BrdU after the 70-day
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Day 0 Day 1 Day 4 Day 10
0.0 4.5 25.0 44.6
2 0.0 5.6 23.6 43.2
3 0.0 5.0 50.0
4 0.0 10.9
Mean ± s.d. 0.0 ± 0.0 6.5 ± 3.0 24 46 ± 3.6
Figure 2 | Six per cent of HSCs stochastically enter the cell cycle each day.
a, HSCs can be isolated by flow cytometry as
CD1501CD48–CD41–lineage–Sca-11c-kit1 cells; these represent only
0.0066 6 0.0003% (0.007% 3 94%) of bone marrow cells but contain all
detectable HSC activity and are very highly enriched for HSCs (nearly 50%
of single cells give long-term multilineage reconstitution in irradiated
mice17). b, BrdU incorporation into HSCs (arrowheads) is evaluated by
immunofluorescence after sorting HSCs onto microscope slides (DAPI is a
nuclear stain). c, d, The percentage of BrdU1 bone marrow cells (c) and
CD1501CD48–CD41–lineage–Sca-11c-kit1 HSCs (d) after various periods
of BrdU administration (3–4 independent experiments with 3–4 mice per
experiment and 200–400 bone marrow cells or 100–400 HSCs counted,
respectively, per mouse). Standard deviations are shown for means that are
based on at least three independent experiments. e, The percentage of HSCs
that enter the cell cycle each day (6%) can be derived by plotting the negative
logarithm of the percentage of HSCs that were BrdU– over time15.
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chase (Fig. 3a). Thus, these calculations predict that few (,20%)
HSCs should retain BrdU after a 70-day chase, irrespective of how
chromosomes are segregated.
To test this we administered BrdU for 10 days to adult mice and
then stained whole bone marrow cells and CD1501CD48–CD41–
lineage–Sca-11c-kit1 HSCs after 40, 70 and 120 days of chase. After
70 days of chase, 0.4 6 0.1% (mean 6 s.d.) of bone marrow cells
and 4.6 6 0.9% of HSCs were BrdU1 (Fig. 3c). This demonstrates
that, as predicted (Fig. 3a), few HSCs retain BrdU. Moreover, only
2.0 6 1.0% of HSCs were BrdU1 after 120 days of chase, demonstrat-
ing that the frequency of BrdU-retaining HSCs continues to decline
over time rather than there being a deeply quiescent subset of HSCs
that retains BrdU indefinitely. Although BrdU-label-retaining cells
were enriched in HSCs by tenfold compared to whole bone marrow
cells, the rarity of HSCs means that only 0.08% of BrdU1 bone
marrow cells were HSCs (0.0066% 3 4.6%/0.4%). BrdU-label reten-
tion is therefore a very insensitive and nonspecific marker of HSCs
because most HSCs did not retain detectable BrdU, and only rare
BrdU-label-retaining cells were HSCs. Very similar results were
obtained when we used flow cytometry to detect BrdU incorporation
(Supplementary Fig. 1) or when HSCs were isolated using different
surface markers (c-kit1Flk-2–lineage–Sca-11 cells; Supplementary
Fig. 2). These data are most consistent with random chromosome
segregation by HSCs and the failure to detect BrdU after approxi-
mately three divisions in the absence of BrdU (Fig. 3a).
According to the immortal strand model, stem cells can incorpo-
rate BrdU into DNA strands that become the ‘older’ strands during
symmetric cell divisions, and these labelled DNA strands would be
retained indefinitely by stem cells that resume asymmetric divisions
(Fig. 1c). To test this, we administered BrdU to newborn mice for
10 days or to cyclophosphamide and granulocyte colony-stimulating
factor (cyclophosphamide/G-CSF)-treated mice for 4 days. The
absolute number of HSCs expands markedly in both newborn18
and cyclophosphamide/G-CSF-mobilized mice19 (indicating sym-
metric divisions), before stabilizing to steady-state levels as mice
enter adulthood or after G-CSF is discontinued. After 10 days of
BrdU treatment in neonatal mice, 93 6 3.7% of bone marrow cells
and 80 6 11% of CD1501CD48–CD41–lineage–Sca-11c-kit1 HSCs
were BrdU1. Seventy days later, 0.1% of bone marrow cells and
6.4 6 2.5% of CD1501CD48–CD41–lineage–Sca-11c-kit1 HSCs
were BrdU1 (Fig. 3d). After 4 days of BrdU treatment in cyclophos-
phamide/G-CSF mobilized mice, 94 6 3% of CD1501CD48–CD41–
lineage–Sca-11c-kit1 HSCs were BrdU1. Seventy days later, 0.1% of
bone marrow cells and 2.1 6 1.1% of CD1501CD48–CD41–lineage–
Sca-11c-kit1 HSCs were BrdU1 (Fig. 3d). Thus, even when BrdU
was administered to symmetrically dividing HSCs, only 2–6% of
HSCs retained the label and only 0.2–0.4% of BrdU-retaining bone
marrow cells were HSCs. We were unable to identify any context in
which BrdU-label retention identified HSCs with sensitivity or
specificity, and none of these results was consistent with the immortal
strand hypothesis.
To address the possibility that the HSCs in the above experiments
might have continued to divide symmetrically after BrdU was
discontinued, we also administered BrdU to mice from 20 to 29 days
postnatally. HSCs are thought to transition from rapidly dividing
cells that have a fetal phenotype to relatively quiescent cells that have
an adult phenotype between 21 and 28 days postnatally18. We
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1 0.0 0.1 0.0
2 0.2 0.1 0.0
3 0.2 0.0 0.2
Mean ± s.d. 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1
Figure 3 | Few HSCs retain BrdU, and most BrdU-retaining bone marrow
cells are not HSCs. a, A model is shown that predicts the fraction of HSCs
that retain BrdU over time after administering BrdU for 10 days, depending
on whether chromosomes segregate asymmetrically or randomly and on the
threshold of BrdU that can be detected by immunofluorescence (0.5n, 0.25n,
0.125n or 0.0625n labelled DNA). b, CD1501CD48–CD41–lineage–Sca-11
c-kit1 HSCs were sorted onto a microscope slide after 10 days BrdU
administration and 70 days chase (without BrdU). Arrowheads identify
BrdU1 cells. c, Shown is the frequency of BrdU1 bone marrow cells and
HSCs after 10 days of BrdU administration and 40, 70 or 120 days of chase.
Standard deviations are shown for means that are based on at least three
independent experiments. d, Shown is the frequency of BrdU1 bone marrow
cells and HSCs after 10 days BrdU administration to neonatal mice followed
by 70 or 120 days of chase, or after 4 days BrdU administration to
cyclophosphamide/G-CSF-mobilized mice followed by 70 days of chase. All
data are based on 3–5 independent experiments with 3 mice per experiment
and 400–700 bone marrow cells or 300–400 HSCs counted per mouse.
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BrdU after a 70-day chase. There was, therefore, no period during
neonatal development when BrdU could be administered in a way
that resulted in retention of BrdU within significant numbers of
HSCs.
To test the immortal strand model directly, we treated mice with
5-chloro-2-deoxyuridine (CldU) for 10 days and then with 5-iodo-2-
deoxyuridine (IdU) for 10 days. If HSCs segregate older and younger
DNA strands asymmetrically, then HSCs should rarely incorporate
both CldU and IdU under steady-state conditions because newly
synthesized (labelled) DNA strands should be segregated to differ-
entiating daughter cells after each division (Fig. 4a). In contrast, if
HSCs segregate older and younger DNA strands randomly then
CldU-labelled HSCs should have the same chance of incorporating
IdU as unlabelled cells, and approximately 25% (50% 3 50%) of
HSCs should be double-labelled (Fig. 4b).
After 10 days of CldU followed by 10–11 days of IdU, we observed
that 14% of HSCs incorporated only CldU, 32% incorporated only
IdU and 27% incorporated both CldU and IdU (Fig. 4c and Sup-
plementary Fig. 4). The frequency of CldU1IdU1 cells (27%) was
therefore similar to the product of the frequencies of total CldU1
cells and total IdU1 cells (41% 3 59% 5 24%), indicating that
CldU1 cells had a similar probability of incorporating IdU as the
other cells. We repeated this experiment by administering mice
with CldU for 60 days followed by IdU for 15 days, and found the
frequency of CldU1IdU1 cells (63%) was again similar to the prod-
uct of the frequencies of total CldU1 cells and total IdU1 cells
(73% 3 84% 5 61%). These results were not significantly affected
by a slow clearance of CldU from mice, because CldU was cleared
in less than 1 day after being discontinued from the drinking water
(Supplementary Fig. 5). These observations directly contradict a key
prediction made by the immortal strand hypothesis, but are as would
be expected by random chromosome segregation.
The foregoing experiments left the formal possibility that if HSCs
divide by a combination of symmetric and asymmetric divisions
in vivo we might underestimate the frequency of HSCs that retain
older DNA strands. To address this we examined the division of
individual HSCs in culture that were isolated from mice treated for
10 days with BrdU. Single CD1501CD48–CD41–lineage–Sca-11c-kit1
HSCs were sorted into cultures under conditions in which half of HSC
divisions give asymmetric outcomes (daughter cells with different
developmental potentials)16. After 2–3 days of culture we observed a
total of 346 colonies in which HSCs had divided once (2 daughter
cells) or twice (3 or 4 daughter cells). Either all daughter cells were
BrdU1 (162 colonies, 46%) or all daughter cells were BrdU– (184
colonies; Fig. 4f), as would be expected by random chromosome
segregation given that 46% of HSCs incorporate BrdU in vivo after
10 days (Fig. 2d). We observed no colonies containing a mixture of
BrdU1 and BrdU– cells after one or two rounds of division. Thus,
these in vitro experiments on individual HSCs failed to detect any
asymmetric segregation of labelled chromosomes.
Our results were not confounded by the effects of BrdU, CldU or
IdU on HSC proliferation, survival or DNA repair. The cell cycle
status (Supplementary Fig. 3) and frequency (data not shown) of
HSCs was not affected by these treatments. BrdU, CldU and IdU
incorporation from DNA repair was not detectable (Supplemen-
tary Fig. 3).
Our results indicate that BrdU-label retention is neither a sensitive
nor a specific marker of HSCs. Nonetheless BrdU-label retention
could be a better marker of stem cells in other tissues. Moreover,
histone–green fluorescent protein retention7 may do a better job of
marking stem cells, including HSCs, because it can be selectively
expressed in subsets of progenitors and may be retained with differ-
ent kinetics than BrdU. Our data demonstrate the need to test the
sensitivity and specificity of BrdU and other label-retention markers
before assuming they mark stem cells with fidelity.
Our data also demonstrate that the immortal strand model2 does
not apply to HSCs and cannot be considered a general model of
stem cell division. Our data do not address whether stem cells from
other tissues asymmetrically segregate chromosomes or whether
HSCs segregate a limited number of chromosomes asymmetrically10.
Nonetheless, asymmetric chromosome segregation cannot be a
mechanism by which HSCs avoid accumulating mutations over time.
METHODS SUMMARY
BrdU, CldU and IdU administration. All experiments used C57BL/
Ka-CD45.2:Thy-1.1 mice. For experiments in adult mice, BrdU (Sigma) was
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Figure 4 | HSCs segregate chromosomes randomly in vivo and in vitro. a, By
the immortal strand model, stem cells sequentially exposed to CldU (for
10 days) and then IdU (for 10 days) would not incorporate both labels, with
the exception of rare cells in the S/G2/M phase of their first division after
switching from CldU into IdU (expected frequency ,3%). b, In contrast, if
chromosome segregation is random then CldU1 stem cells would have the
same probability of incorporating IdU as unlabelled cells (expected frequency
of CldU1IdU1 HSCs is ,25%). c, CldU was administered to mice for 10 days
followed by IdU for 10–11 days, and CD1501CD48–CD41–lineage–Sca-11
c-kit1 HSCs were stained. Examples of HSCs that incorporated neither
label, only CldU, only IdU or both labels are shown (mean 6 sd; data are
based on two independent experiments with 2 or 3 mice per experiment and
100–250 HSCs per mouse). HSCs from BrdU-treated mice divided once (d) or
twice (e) in culture to form daughter cells. f, The progeny of these HSCs were
either all BrdU1 or all BrdU–. We detected no clones in which label was
asymmetrically segregated to a subset of daughter cells.
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administered when the mice were 8–10 weeks of age. Mice were given an intra-
peritoneal injection of 100 mg BrdU per kg body mass in Dulbecco’s phosphate
buffered saline (DPBS; Gibco) and were maintained on 1 mg ml–1 BrdU in the
drinking water for 1–10 days. Amber bottles containing BrdU water were chan-
ged every 1–3 days. For retention studies, BrdU water was replaced with regular
water and the mice were maintained for 40–120 days before analysis.
BrdU injections into neonatal mice were performed as described20. Beginning
within 3 days after birth, neonatal mice were injected subcutaneously with 50 mg
BrdU per kg body weight twice daily for 10 days. Mice were weighed every 2 days
and the dose of BrdU was adjusted.
To assess BrdU retention after cytokine mobilization, adult mice were injected
with cyclophosphamide (200 mg kg–1; Bristol-Myers Squibb) and then on each
of the 4 subsequent days they were injected with 250mg kg–1day–1 of human
G-CSF (Amgen)19. On the fourth day of G-CSF injection, a single intraperitoneal
injection of 100 mg BrdU per kg body mass was given and the mice were put on
1 mg ml–1 BrdU water for 4 additional days. The mice were then returned to
regular water for 70 days before analysis.
For CldU and IdU experiments, mice were given an intraperitoneal injection
of 100 mg CldU per kg body mass in DPBS and were maintained on drinking
water containing 1 mg ml–1 CldU (Sigma) for 10 days. Mice were then given an
intraperitoneal injection of 100 mg IdU per kg body mass in DPBS, and were
switched to drinking water containing 1 mg ml–1 IdU (Sigma) for 10–11 days
before being killed.
For details related to the flow cytometric isolation of HSCs and CldU, IdU and
BrdU staining, see Methods.
BrdU segregation in cultured HSCs. Single CD1501CD48–CD41–lineage–Sca-11
c-kit1 HSCs were sorted from BrdU-treated mice into a V-bottom 96-well
plate containing Stempro-34 medium (Invitrogen) supplemented with 2 mM
L-glutamine, 50 mM 2-mercaptoethanol (Sigma), murine IL-3 (10 ng ml–1),
murine SCF (100 ng ml–1) and murine Tpo (100 ng ml–1; all cytokines were
obtained from R&D Systems) with 10% charcoal absorbed fetal bovine serum
(Cocalico Biologicals Inc.), and were cultured for 2–3 days in low-oxygen
chambers21. For analysis, plates were centrifuged at 500g for 10 min; cells from
each colony were then pipetted onto individual wells of Teflon-printed glass
slides and were allowed to dry overnight before staining for BrdU and 4,6-
diamidino-2-phenylindole (DAPI).
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
Flow cytometric isolation of HSCs. Bone marrow cells were flushed from the
long bones (tibias and femurs) with Hank’s buffered salt solution (HBSS) with-
out calcium or magnesium supplemented with 2% heat-inactivated calf serum
(GIBCO). Cells were triturated and filtered through a nylon screen (45 mm, Sefar
America) to obtain a single-cell suspension. For isolation of Flk2–lineage–Sca-11
c-kit1 HSCs, whole bone marrow cells were incubated with phycoerythrin-
conjugated monoclonal antibodies against lineage markers including B220
(6B2), CD3 (KT31.1), CD4 (GK1.5), CD8 (53-6.7), Gr-1 (8C5), Mac-1 (M1/70),
Flk-2 (A2F10.1), Ter119 and IgM in addition to fluorescein isothiocyanate (FITC)-
conjugated anti-Sca-1 (Ly6A/E) and biotin-conjugated anti-c-kit (2B8) antibodies,
followed by streptavidin allophycocyanin (APC)-Cy7. For isolation of CD1501
CD48–CD41–lineage–Sca-11c-kit1 HSCs, whole bone marrow cells were incu-
bated with phycoerythrin-conjugated anti-CD150 (TC15-12F12.2; BioLegend),
FITC-conjugated anti-CD48 (HM48-1; BioLegend), FITC-conjugated anti-
CD41 (MWReg30; BD Pharmingen), APC-conjugated anti-Sca-1 (E13-6.7) and
biotin-conjugated anti-c-kit (2B8) antibodies, in addition to FITC-conjugated
antibodies against Ter119, B220 (6B2), Gr-1 (8C5) and CD2 (RM2-5). HSCs were
frequently pre-enriched by selecting c-kit1 cells using paramagnetic microbeads
and autoMACS (Miltenyi Biotec). All flow cytometry was performed on a
FACSVantage SE-dual laser, three-line flow cytometer (Becton-Dickinson).
BrdU staining. Staining for BrdU on slides was performed as previously
described using an anti-BrdU antibody (clone BU1/75, Accurate Chemical and
Scientific Corp.)15. HSCs were sorted and then resorted (to ensure purity) onto
glass slides in 25–100-cell spots, allowed to dry for 1 h and stored at 280 uC for
up to 4 weeks. Slides were thawed at room temperature (23 uC) for 15 min, fixed
in 70% ethanol at –20 uC for 30 min, rinsed in 0.1 M phosphate buffer twice,
incubated in 2 M HCl with 0.8% Triton in phosphate buffer for 30 min, incu-
bated in 0.1 M sodium borate (pH 8.5) for 15 min, and rinsed in 0.1 M phosphate
buffer at room temperature, then at 37uC, and finally at room temperature again.
The slides were then incubated with 0.3% Triton in 0.1 M phosphate buffer
supplemented with 5% goat serum for 1 h at 4 uC. Slides were incubated at
4 uC overnight with a primary anti-BrdU antibody that specifically recognizes
BrdU and CldU but does not recognize IdU (clone BU1/75, Accurate Chemical
and Scientific Corp.). Slides were then rinsed in 0.1 M phosphate buffer twice
and were incubated with Alexa488-conjugated goat anti-rat IgG (Invitrogen-
Molecular Probes) for 2 h at room temperature. Slides were rinsed in 0.1 M
phosphate buffer twice and were incubated with DAPI for 1 h at room temper-
ature. Finally, slides were rinsed 3 times in 0.1 M phosphate buffer, the excess
buffer was shaken off and the slides were mounted in 70% glycerol in PBS.
Images were gathered using an Olympus BX-51 fluorescence microscope
equipped with a Cooke Pixelfly CCD camera.
In some experiments, BrdU incorporation was measured by flow cytometry
using an antibody directly conjugated to APC (APC BrdU flow kit, BD
Pharmingen). Sorted samples were fixed and permeabilized according to manu-
facturer’s instructions, incubated in 2 M HCl for 30 min at room temperature,
neutralized in 0.1 M sodium borate (pH 8.5), washed in 0.5% Triton in DPBS,
stained with anti-BrdU APC and resuspended in DAPI (10mg ml–1) before FACS
analysis. All flow cytometry was performed on a FACSVantage SE-dual laser,
three-line flow cytometer (Becton-Dickinson).
CldU and IdU double-labelling. Slides were processed as for BrdU analysis with
the addition of a subsequent set of staining steps using a second anti-IdU anti-
body (clone B44, BD Pharmingen) that does not recognize CldU. Slides were
incubated at room temperature in anti-IdU antibody for 2–3 h. Immuno-
fluorescence was developed using a Cy3-conjugated anti-mouse IgG secondary
antibody with minimal cross reactivity to rat IgG (Jackson Immunoresearch).
Cells isolated from mice that had only received CldU, had only received IdU, or
had received neither were processed in parallel with experimental samples and
demonstrated no cross-reactivity or background staining from primary or
secondary antibodies.
Analysis of cell cycle distribution and cell death in HSCs. Cell cycle distri-
bution was analysed by Hoechst 33342 (Invitrogen-Molecular Probes) staining.
CD1501CD48–CD41–lineage–Sca-11c-kit1 HSCs were sorted and resorted into
ice-cold 70% ethanol and stored at –20 uC overnight. Cells were resuspended in
PBS containing 0.02 mg ml–1 Hoechst 33342, incubated for 30 min and analysed
by flow cytometry using an ultraviolet laser.
For activated caspase-3 staining, frozen slides bearing sorted CD1501CD48–
CD41–lineage–Sca-11c-kit1 HSCs or sections through embryonic day 11 mouse
forebrain were thawed at room temperature for 10 min, fixed at room temper-
ature in 10% buffered neutral formalin (VWR) for 10 min, rinsed in 0.1 M
phosphate buffer twice and blocked with 0.3% Triton in 0.1 M phosphate buffer
supplemented with 5% goat serum for 1 h at 4 uC. Slides were then incubated
with anti-activated caspase-3 antibody (BD Pharmingen) at room temperature
for 2 h, and rinsed in 0.1 M phosphate buffer twice and incubated with Alexa488-
conjugated goat anti-rabbit IgG (Invitrogen-Molecular Probes) for 1 h at room
temperature. The slides were then rinsed in 0.1 M phosphate buffer twice and
incubated with DAPI for 30 min at room temperature. Finally, slides were rinsed
three times in 0.1 M phosphate buffer, the excess buffer was shaken off and the
slides were mounted in 70% glycerol in PBS. Images were collected using a
fluorescence microscope.
To test for the incorporation of BrdU due to DNA repair, BrdU was adminis-
tered to adult mice for 12 h followed by irradiation with 100 rad from a
Gammacell40 Extractor (MDS Nordion) followed by 48 h of further BrdU
administration. CD1501CD48–CD41–lineage–Sca-11c-kit1 HSCs were then
sorted onto slides and stained for BrdU as described above.
Mathematical models of BrdU uptake and retention. To model the uptake
and retention of BrdU in a population of stem cells we assumed that for days
0 through to T the stem cells are exposed to adequate BrdU so that cells incorp-
orate BrdU when they divide. On the basis of our data, a random 6.0% of HSCs
enter the cell cycle each day. At day T, the BrdU supply is removed and the level of
BrdU incorporated into the chromosomes decreases for every cell division after
day T. The rate at which BrdU is diluted from cells during this chase period
depends on how the cells segregate their chromosomes. If chromosomes segre-
gate randomly then, irrespective of whether stem cells divide asymmetrically or
symmetrically with respect to daughter-cell fate, BrdU-labelled chromosomes
will stochastically become diluted over time: on average, the BrdU label will be
diluted by half during each round of division and multiple divisions will be
required to dilute the BrdU label to the point at which it is no longer detectable
by immunohistochemistry. This is modelled as case 1 (see below) for asymmet-
rically dividing cells. In contrast, according to the immortal strand model2, stem
cells divide asymmetrically under steady-state conditions and BrdU is preferen-
tially incorporated into newly synthesized DNA strands that are asymmetrically
segregated into differentiating daughter cells with each round of division. Under
these assumptions, modelled as case 2 (see below), stem cells retain only the
unlabelled older DNA strands once BrdU is withdrawn.
Case 1: random segregation of chromosomes. When chromosomes are allowed
to segregate randomly, BrdU could be incorporated into one or two DNA strands
within each chromosome, depending on the number of times a stem cell divides
during the period of BrdU incorporation and the way in which the chromosomes
segregate. To model the rate of BrdU incorporation: y0 represents the fraction of
cells without BrdU; y1 represents the fraction of cells with one strand BrdU
1 after
only one division; y2 represents the fraction of cells with both strands BrdU
1
after two or more divisions; and a represents the proliferation rate of stem cells
(we observed 6.0% of HSCs enter the cell cycle per day). Cell death was not
incorporated into this model because we did not observe significant cell death or











In equation (1), cells leave the y0 population when they divide. In equation (2),
cells from the y0 population are added into the y1 population through the
incorporation of BrdU into one of the DNA strands. Cells leave the y1 population
when they divide. In equation (3), cells from the y1 population are added into the
y2 population through further incorporation of BrdU through cell division.
To determine the frequency of BrdU1 stem cells at any time after the addition
of BrdU, we solve the system of ordinary differential equations, with all HSCs
initially being unlabelled before BrdU administration. Similar equations have
been used previously to model BrdU incorporation and depletion from other
cells22.
At day T (when BrdU is removed), we determine the total number of BrdU1
stem cells by adding the y1 and y2 populations. Cells in the y1 population have a
BrdU level of 1, whereas y2 cells have a BrdU level of up to 2. To model the rate at
which these cells lose BrdU during subsequent divisions after removing BrdU, we
used the following: y10 represents the fraction of cells, initially with one labelled
DNA strand, that undergoes zero divisions after day T; y11 represents the fraction
of cells, initially with one labelled DNA strand, that undergoes one division after
day T; y1N represents the fraction of cells, initially with one labelled DNA strand,
that undergoes N divisions after day T; y20 represents the fraction of cells, initially
with two labelled DNA strands, that undergoes zero divisions after day T; y21
represents the fraction of cells, initially with two labelled DNA strands, that
doi:10.1038/nature06115
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undergoes one division after day T; y2N represents the fraction of cells, initially
with two labelled DNA strands, that undergoes N divisions after day T. Cells
move from y1(k–1) to y1k at the proliferation rate a (cells move in y2k similarly).



















With each cell division, the cell’s BrdU level is decreased by half. For instance,
cells in y10 have a BrdU level of 1, cells in y11 have half as much BrdU on average,
and cells in y12 have one-quarter as much BrdU on average, and so on. Similarly,
cells in y20 have a BrdU level of 2, cells in y21 have BrdU level 1, cells in y22 have a
BrdU level of 0.5, and so on. We can determine the total fraction of cells that have
a BrdU level that is above a minimum detection level (which can be set at any
desired level in the simulations) by adding all relevant populations at any time
after day T.
This set of ordinary differential equations is solved for initial conditions that
are determined by the observed results of the BrdU incorporation at time T. In
this way, it is possible to plot the frequency of BrdU1 HSCs over time, depending
on whether it takes 1, 2, 3 or 4 rounds of division to dilute BrdU to the point at
which it is no longer detectable (Fig. 3a). Note that one round of division
corresponds to a 2-fold dilution of BrdU whereas four rounds of division corre-
spond to 16-fold dilution. Our empirical data indicate that approximately three
rounds of division are required to dilute BrdU to the point that it is no longer
detectable in HSCs.
Case 2: asymmetric chromosome segregation. In this model, only one strand of
DNA within each chromosome in stem cells can contain BrdU, irrespective of
how long BrdU is administered (although the proportion of labelled stem cells





In equation (4), cells from the y0 population are added into the y1 population
through the incorporation of BrdU into one of the DNA strands.
As before, to determine the proportion of cells within each population at the
end of day T, we solve the system of ordinary differential equations with initial
conditions corresponding to the case in which initially all HCSs are unlabelled
before BrdU administration. Cells in population y0 do not contain any BrdU,
whereas those in y1 have a BrdU level of one.
To study the process by which cells lose BrdU label, we took all cells containing
BrdU at day T (all cells in population y1 and monitored BrdU loss through cell
division in the absence of BrdU). In this case, the asymmetric segregation of
chromosomes means that all dividing stem cells will lose all BrdU label in a single
division in the absence of BrdU. Therefore, the fraction of stem cells that remain
BrdU1 at time T simplifies to the fraction of BrdU1 HSCs that do not divide
after removing BrdU. Cells move from y10 (and lose their BrdU label) at the




This differential equation with initial condition y10(0) 5 y1(T) determines the
fraction of HSCs that retain BrdU over time, according to the immortal strand
hypothesis.
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